Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to treat Type 2 diabetes and obesity. Recent research has expanded their potential applications ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Discover the FDA-approved indications for GLP-1 receptors, including diabetes, weight loss, and cardiovascular disease. Learn brand-name and generic options.

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...

American host and television producer Oprah Winfrey recently shared her initial experience of taking the weight loss drug GLP ...

(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA ... and clinicians about the short-term safety of these drugs,” the authors write. “Nevertheless, evidence was ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...